Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease

被引：8

作者：

Schrauben, Michael ^{[1
]}

Dempster, Emma ^{[1
]}

Lunnon, Katie ^{[1
]}

机构：

[1] Exeter Univ, Univ Exeter, Sch Med, Exeter, Devon, England

来源：

BRAIN PATHOLOGY | 2020年 / 30卷 / 05期

关键词：

Alzheimer's disease (AD); CRISPR; epigenetics; genetics; genome editing; MOUSE MODELS; CRISPR-CAS9; SYSTEM; APOLIPOPROTEIN-E; DNA METHYLATION; HUMAN GENOME; RNA; RISK; ACTIVATION; MECHANISMS; GENERATION;

D O I：

10.1111/bpa.12881

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Recent studies have highlighted a potential role of genetic and epigenetic variation in the development of Alzheimer's disease. Application of the CRISPR-Cas genome-editing platform has enabled investigation of the functional impact that Alzheimer's disease-associated gene mutations have on gene expression. Moreover, recent advances in the technology have led to the generation of CRISPR-Cas-based tools that allow for high-throughput interrogation of different risk variants to elucidate the interplay between genomic regulatory features, epigenetic modifications, and chromatin structure. In this review, we examine the various iterations of the CRISPR-Cas system and their potential application for exploring the complex interactions and disruptions in gene regulatory circuits that contribute to Alzheimer's disease.

引用

页码：992 / 1004

页数：13

共 50 条

[1] Using Novel Technologies to Improve upon Gene-Editing Therapeutics for Alzheimer's Disease
Malhotra, Sahil
MOLECULAR THERAPY, 2021, 29 (04) : 187 - 188
[2] Epigenetic dysregulation in Alzheimer's disease: cause or consequence?
van den Hove, Daniel L. A.
Kenis, Gunter
Rutten, Bart P. F.
EPIGENOMICS, 2014, 6 (01) : 9 - 11
[3] The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?
Millan, Mark J.
DIALOGUES IN CLINICAL NEUROSCIENCE, 2014, 16 (03) : 373 - 393
[4] CRISPR/Cas9-based gene-editing technology for sickle cell disease
Ma, Liangliang
Yang, Shanglun
Peng, Qianya
Zhang, Jingping
Zhang, Jing
GENE, 2023, 874
[5] Genetic and functional analyses of progranulin gene variants in Alzheimer's disease
Fenoglio, C.
Galimberti, D.
Cortini, F.
Kauwe, J. S. K.
Venturelli, E.
Guidi, I.
Scalabrini, D.
Villa, C.
Mayo, K.
Valle, E. Dalla
Lovati, C.
Mariani, C.
Bresolin, N.
Goate, A. M.
Scarpini, E.
JOURNAL OF NEUROLOGY, 2008, 255 : 47 - 47
[6] User-Friendly Technology the Key to Gene-Editing's Bloom: Market for Gene-Editing Tools Estimated at $608m and Growing as New Applications Are Found
Carlson, Bruce
HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2016, 27 (04) : 137 - 139
[7] Genetic variation, functional genomics and pharmacogenomics in Alzheimer disease
Cacabelos, R
NEUROBIOLOGY OF AGING, 2004, 25 : S4 - S4
[8] Science Runs and the Debate Brakes: Somatic Gene-Editing as a New Tool for Gender-Specific Medicine in Alzheimer's Disease
Tozzo, Pamela
Zullo, Silvia
Caenazzo, Luciana
BRAIN SCIENCES, 2020, 10 (07)
[9] Genetic variation in Clusterin gene and Alzheimer's disease risk in Han Chinese
Yu, Jin-Tai
Ma, Xiao-Ying
Wang, Ying-Li
Sun, Lei
Tan, Lin
Hu, Nan
Tan, Lan
NEUROBIOLOGY OF AGING, 2013, 34 (07) : 1921.e17 - 1921.e23
[10] Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease
Bodner, SM
Berrettini, W
van Deerlin, V
Bennett, DA
Wilson, RS
Trojanowski, JQ
Arnold, SE
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2005, 134B (01) : 1 - 5

← 1 2 3 4 5 →